Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | N550H |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FGFR2 N550H (corresponds to N549H in the canonical isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N550H results in increased Fgfr2 kinase activity, as well as increased Fgfr2 phosphorylation and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597). |
Associated Drug Resistance | Y |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 N550H |
Transcript | NM_022970.4 |
gDNA | chr10:g.121498522T>G |
cDNA | c.1648A>C |
Protein | p.N550H |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001144914.1 | chr10:g.121487993T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121487993T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144919.2 | chr10:g.121488065T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_022970 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144919.1 | chr10:g.121488065T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_022970.4 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144919 | chr10:g.121488065T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144913 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144914 | chr10:g.121487993T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_022970.3 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01888562 | Phase I | Ponatinib | Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma | Withdrawn | 0 |